Skip to main content

Advertisement

SpringerLink
Log in

Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Synchronous bilateral breast cancers frequently share the same estrogen receptor (ER) status, yet may differ in other histopathologic features. We sought to examine concordance rates of Oncotype DX recurrence score (RS) testing in women with synchronous bilateral ER-positive breast cancer.

Methods

Institutional databases were reviewed to identify patients with synchronous (within 6 months) bilateral primary invasive breast cancer and multiple RSs. RSs were stratified by risk group (RS < 18, low; RS 18–30, intermediate; RS ≥ 31, high) and considered discordant if they reflected different risk groups.

Results

From 2005–2014, a total of 115 patients presented with synchronous bilateral invasive breast cancer; 43 (37 %) had two RSs available. Median patient age was 60 years (42–84), median tumor size was 1.2 cm (0.5–3.7), and all cases were HER2 negative and node negative. Of 86 RSs, 63 (73 %) were low risk, 20 (23 %) were intermediate risk, and 3 (3 %) were high risk. RSs were concordant in 29 (67 %) patients. Patients with concordant RSs were older (62 years vs. 56 years) and had median levels of progesterone receptor (PR) expression that were higher and more similar—80 and 85 % for bilateral cancers, respectively, compared with 55 and 75 % for bilateral cancers in discordant cases. Discordant RS led to a treatment change in 8/14 (57 %) cases.

Conclusions

Among women with synchronous bilateral ER-positive HER2-negative breast cancer, RSs were concordant in 67 % of cases. Concordance rates may be higher in older women or among those with comparable levels of PR expression. These data suggest that testing of both tumors should be considered in patients who are candidates for adjuvant chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008;26(25):4063–71.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312.

    Article  PubMed  CAS  Google Scholar 

  3. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.

    Article  PubMed  CAS  Google Scholar 

  4. Albain KS, Paik S, van’tVeer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast. 2009;18(Suppl 3):S141–5.

    Article  PubMed  Google Scholar 

  5. Carlson JJ, Roth JA. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;141(1):13–22.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Tang G, Shak S, Paik S, et al. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat. 2011;127(1):133–42.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Gollamudi SV, Gelman RS, Peiro G, et al. Breast-conserving therapy for stage I–II synchronous bilateral breast carcinoma. Cancer. 1997;79(7):1362–9.

    Article  PubMed  CAS  Google Scholar 

  8. Kollias J, Ellis IO, Elston CW, et al. Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol. 1999;25(6):584–9.

    Article  PubMed  CAS  Google Scholar 

  9. Toole MJ, Kidwell KM, Van Poznak C. Oncotype dx results in multiple primary breast cancers. Breast Cancer (Auckl). 2014;8:1–6.

    Google Scholar 

  10. Kilgore AR. The incidence of cancer in the second breast. JAMA. 1921;77:454–7.

    Article  Google Scholar 

  11. Haagensen CD. The physiology of the breast as it concerns the clinician. Am J Obstet Gynecol. 1971;109(2):206–9.

    PubMed  CAS  Google Scholar 

  12. Schwentner L, Wolters R, Wischnewsky M, et al. Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients. Breast. 2012;21(2):171–7.

    Article  PubMed  Google Scholar 

  13. Hartman M, Czene K, Reilly M, et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol. 2007;25(27):4210–6.

    Article  PubMed  Google Scholar 

  14. Holm M, Tjonneland A, Balslev E, et al. Prognosis of synchronous bilateral breast cancer: a review and meta-analysis of observational studies. Breast Cancer Res Treat. 2014;146(3):461–75.

    Article  PubMed  Google Scholar 

  15. de la Rochefordiere A, Asselain B, Scholl S, et al. Simultaneous bilateral breast carcinomas: a retrospective review of 149 cases. Int J Radiat Oncol Biol Phys. 1994;30(1):35–41.

    Article  PubMed  Google Scholar 

  16. Irvine T, Allen DS, Gillett C, et al. Prognosis of synchronous bilateral breast cancer. Br J Surg. 2009;96(4):376–80.

    Article  PubMed  CAS  Google Scholar 

  17. Nichol AM, Yerushalmi R, Tyldesley S, et al. A case-match study comparing unilateral with synchronous bilateral breast cancer outcomes. J Clin Oncol. 2011;29(36):4763–8.

    Article  PubMed  Google Scholar 

  18. Schmid SM, Pfefferkorn C, Myrick ME, et al. Prognosis of early-stage synchronous bilateral invasive breast cancer. Eur J Surg Oncol. 2011;37(7):623–8.

    Article  PubMed  CAS  Google Scholar 

  19. Imyanitov EN, Suspitsin EN, Grigoriev MY, et al. Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas. Int J Cancer. 2002;100(5):557–64.

    Article  PubMed  CAS  Google Scholar 

  20. Janschek E, Kandioler-Eckersberger D, Ludwig C, et al. Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat. 2001;67(1):1–8.

    Article  PubMed  CAS  Google Scholar 

  21. Shibata A, Tsai YC, Press MF, et al. Clonal analysis of bilateral breast cancer. Clin Cancer Res. 1996;2(4):743–8.

    PubMed  CAS  Google Scholar 

  22. Chen JJ, Wang Y, Xue JY, et al. A clinicopathological study of early-stage synchronous bilateral breast cancer: a retrospective evaluation and prospective validation of potential risk factors. PLoS One. 2014;9(4):e95185.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Hartman M, Czene K, Reilly M, et al. Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol. 2005;6(6):377–82.

    Article  PubMed  Google Scholar 

  24. Jobsen JJ, van der Palen J, Ong F, et al. Synchronous, bilateral breast cancer: prognostic value and incidence. Breast. 2003;12(2):83–8.

    Article  PubMed  CAS  Google Scholar 

  25. Buggi F, Folli S, Curcio A, et al. Multicentric/multifocal breast cancer with a single histotype: is the biological characterization of all individual foci justified? Ann Oncol. 2012;23(8):2042–6.

    Article  PubMed  CAS  Google Scholar 

  26. Saad RS, Denning KL, Finkelstein SD, et al. Diagnostic and prognostic utility of molecular markers in synchronous bilateral breast carcinoma. Mod Pathol. 2008;21(10):1200–7.

    Article  PubMed  CAS  Google Scholar 

  27. Coradini D, Oriana S, Mariani L, et al. Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? Eur J Cancer. 1998;34(6):825–30.

    Article  PubMed  CAS  Google Scholar 

  28. Hungness ES, Safa M, Shaughnessy EA, et al. Bilateral synchronous breast cancer: mode of detection and comparison of histologic features between the 2 breasts. Surgery. 2000;128(4):702–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This study was funded in part through National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748, and supported in part by the Breast Cancer Alliance.

Disclosure

Maria Karsten, Michelle Stempel, Julia Radosa, Sujata Patil, and Tari A. King have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Maria Karsten MD, Michelle Stempel MPH, Julia Radosa MD & Tari A. King MD

  2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Sujata Patil PhD

Authors
  1. Maria Karsten MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle Stempel MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julia Radosa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sujata Patil PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tari A. King MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tari A. King MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karsten, M., Stempel, M., Radosa, J. et al. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer. Ann Surg Oncol 23, 471–476 (2016). https://doi.org/10.1245/s10434-015-4841-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-015-4841-4

Keywords

Search

Navigation